ELREXFIO® (elranatamab-bcmm) Patient Financial Support

For patients prescribed ELREXFIO and their care partners, Pfizer Oncology Together can provide support that includes financial assistance options for ELREXFIO, regardless of insurance coverage. Learn more about the support that your dedicated Patient Access Navigator can provide.

As little as

Eligible* patients with commercial insurance^† may pay as little as $0 for each ELREXFIO treatment^‡

Limits, terms, and conditions apply.

Commercially insured

For eligible patients with commercial, private, employer, or state health insurance marketplace coverage:

Co-pay assistance: Eligible,* commercially insured patients^† may pay as little as $0 per treatment for ELREXFIO, regardless of income.^‡ Limits, terms, and conditions apply. Patients may receive up to $25,000 per product in savings annually.

Nationally, 94% of commercially insured patients are eligible for coverage.^§

Apply today

Medicare/government insured

For eligible patients with Medicare, Medicaid, and other government insurance plans, or a financial need:

Pfizer Oncology Together can help you find financial support that may be available from alternate funding resources. These resources exist independently of Pfizer and have their own eligibility criteria and application processes.

Nationally, 100% of Medicare patients are eligible for coverage.^§||

Uninsured

If you do not have any form of healthcare coverage and may be eligible:

Pfizer Oncology Together can check your eligibility for Medicaid and help you understand how to apply.

*Co-pay Program Terms and Conditions

By using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

The Pfizer Oncology Together Co-pay Savings Program for Injectables for ELREXFIO is not valid for patients who are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
Program offer is not valid for cash-paying patients.
With this program, eligible patients may pay as little as $0 co-pay per ELREXFIO treatment, subject to a maximum benefit of $25,000 per calendar year for out-of-pocket expenses for ELREXFIO, including co-pays or coinsurances.
The amount of any benefit is the difference between your co-pay and $0.
After the maximum of $25,000, you will be responsible for the remaining monthly out-of-pocket costs.
Patient must have private insurance with coverage of ELREXFIO.
This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other private health or pharmacy benefit programs.
You must deduct the value of this assistance from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
You are responsible for reporting use of the program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the program, as may be required.
You should not use the program if your insurer or health plan prohibits use of manufacturer co-pay assistance programs.
Patient must be 18 years of age or older for redemption of co-pay card.
This program is not valid where prohibited by law.
This program cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
Co-pay card will be accepted only at participating pharmacies.
This program is not health insurance.
This program is good only in the U.S. and Puerto Rico.
This program is limited to 1 per person during this offering period and is not transferable.
No other purchase is necessary.
Data related to your redemption of the program assistance may be collected, analyzed, and shared with Pfizer for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other assistance redemptions and will not identify you.
Pfizer reserves the right to rescind, revoke, or amend this program without notice.
This program may not be available to patients in all states.
For more information about Pfizer, visit Pfizer.com.
For more information about the Pfizer Oncology Together Co-pay Savings Program for Injectables, visit PfizerOncologyTogether.com, call 1-877-744-5675, or write to:

Pfizer Oncology Together Co-pay Savings Program for Injectables

P.O. Box 220366

Charlotte, NC 28222

Program terms and offer will expire at the end of each calendar year. Before the calendar year ends, you will receive information and eligibility requirements for continued participation.

^†For patients to be eligible for the Injectables Co-pay Program for ELREXFIO, they must have commercial insurance that covers ELREXFIO and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-pay Program for ELREXFIO benefits will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for ELREXFIO administered in the outpatient setting.

^‡The Injectables Co-pay Program for ELREXFIO will pay the co-pay for ELREXFIO up to the annual assistance limit of $25,000 per calendar year per patient.

^§Coverage data are sourced from Managed Markets Insight & Technology (MMIT) and are current as of April 2025. The information provided is not a guarantee of coverage or payment (partial or full) and is subject to change without notice. Individual plans vary, and this may not include all plans.

^||Not all Medicare Advantage plans have published policies, and some may require a medical exception. 20% patient cost sharing may apply.

Style

Colist